CN1031824C - 新的噻唑烷酮和噁唑烷酮衍生物的制备方法 - Google Patents

新的噻唑烷酮和噁唑烷酮衍生物的制备方法 Download PDF

Info

Publication number
CN1031824C
CN1031824C CN92103119A CN92103119A CN1031824C CN 1031824 C CN1031824 C CN 1031824C CN 92103119 A CN92103119 A CN 92103119A CN 92103119 A CN92103119 A CN 92103119A CN 1031824 C CN1031824 C CN 1031824C
Authority
CN
China
Prior art keywords
formula
compound
carbon atoms
group
atom
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN92103119A
Other languages
English (en)
Chinese (zh)
Other versions
CN1066067A (zh
Inventor
石原贞夫
齐藤富士夫
吉冈孝雄
小池博之
三宝茂树
水野洋史
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sankyo Co Ltd
Original Assignee
Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co Ltd filed Critical Sankyo Co Ltd
Publication of CN1066067A publication Critical patent/CN1066067A/zh
Application granted granted Critical
Publication of CN1031824C publication Critical patent/CN1031824C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/14—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
  • Silver Salt Photography Or Processing Solution Therefor (AREA)
CN92103119A 1991-03-27 1992-03-27 新的噻唑烷酮和噁唑烷酮衍生物的制备方法 Expired - Fee Related CN1031824C (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
JP63088/91 1991-03-27
JP6308891 1991-03-27
JP10275191 1991-05-08
JP102751/91 1991-05-08
JP33030491 1991-12-13
JP330304/91 1991-12-13

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN95106819A Division CN1096265C (zh) 1991-03-27 1995-05-26 含新的噻唑烷酮和噁唑烷酮衍生物的药物组合物的制备方法

Publications (2)

Publication Number Publication Date
CN1066067A CN1066067A (zh) 1992-11-11
CN1031824C true CN1031824C (zh) 1996-05-22

Family

ID=27298042

Family Applications (2)

Application Number Title Priority Date Filing Date
CN92103119A Expired - Fee Related CN1031824C (zh) 1991-03-27 1992-03-27 新的噻唑烷酮和噁唑烷酮衍生物的制备方法
CN95106819A Expired - Fee Related CN1096265C (zh) 1991-03-27 1995-05-26 含新的噻唑烷酮和噁唑烷酮衍生物的药物组合物的制备方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN95106819A Expired - Fee Related CN1096265C (zh) 1991-03-27 1995-05-26 含新的噻唑烷酮和噁唑烷酮衍生物的药物组合物的制备方法

Country Status (23)

Country Link
US (2) US5298516A (enExample)
EP (1) EP0506434B1 (enExample)
JP (1) JPH0780859B2 (enExample)
KR (1) KR0152097B1 (enExample)
CN (2) CN1031824C (enExample)
AT (1) ATE118770T1 (enExample)
AU (1) AU647599B2 (enExample)
CA (1) CA2064108C (enExample)
CZ (1) CZ282529B6 (enExample)
DE (1) DE69201451T2 (enExample)
DK (1) DK0506434T3 (enExample)
ES (1) ES2072095T3 (enExample)
FI (1) FI106260B (enExample)
HK (1) HK123595A (enExample)
HU (2) HU217969B (enExample)
IE (1) IE67383B1 (enExample)
IL (1) IL101395A (enExample)
IS (1) IS1746B (enExample)
NO (1) NO304311B1 (enExample)
NZ (1) NZ242154A (enExample)
PH (1) PH30493A (enExample)
RU (1) RU2055073C1 (enExample)
TW (1) TW226015B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3454531B2 (ja) * 1991-11-07 2003-10-06 三共株式会社 ニトロキシアルキルアミド誘導体
JPH08507773A (ja) * 1993-03-15 1996-08-20 ビイク ネダーラント ベスローテン フェンノートシャップ 病的に高い眼圧の処置のための置換硝酸アルキルの使用
DE4429461A1 (de) * 1994-08-19 1996-02-22 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
MX9704435A (es) * 1994-12-15 1997-10-31 Sankyio Company Ltd Compuestos de tiazolidinona y agente terapeutico o agente de prevencion para angina de pecho, que comprende los compuestos como un ingrediente activo.
NZ302391A (en) * 1995-03-02 1999-04-29 Sankyo Co Optically active thiazolidinone derivatives having vessel dilating and an anti-angina pectoris action and use thereof as pharmaceuticals
US5925658A (en) * 1995-03-02 1999-07-20 Sankyo Company, Limited Optically active thiazolidinone derivative
AU6016496A (en) * 1995-06-14 1997-01-15 Sankyo Company Limited Antianginal drug comprising nitroxy derivative as active ingredient
BE1010768A3 (nl) * 1996-11-26 1999-01-05 Dsm Nv Een werkwijze voor de bereiding van alpha-aminozuuramiden, alpha-aminozuren en derivaten ervan.
IL120531A (en) 1997-03-26 2006-12-31 Yissum Res Dev Co Nitric oxide donors and pharmaceutical compositions containing them
WO2002069967A1 (en) * 2001-03-01 2002-09-12 Sankyo Company, Limited Percutaneous absorption compositions
CA2842106A1 (en) * 2011-07-28 2013-01-31 Promentis Pharmaceuticals, Inc. Cysteine prodrugs
US10239847B1 (en) 2016-03-03 2019-03-26 Cellactin Method for 2-oxothiazolidine-4-carboxylic acid for cellular glutathione

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200640A (en) * 1976-04-02 1980-04-29 Chugai Seiyaku Kabushiki Kaisha Nitric ester of N-(2-hydroxyethyl)nicotinamide and pharmaceutical use
GB8717068D0 (en) * 1987-07-20 1987-08-26 Fujisawa Pharmaceutical Co Nitric ester derivative
DE69011930T2 (de) * 1989-04-21 1995-01-19 Du Pont Fungizide Oxazolidinone.

Also Published As

Publication number Publication date
NO921159L (no) 1992-09-28
IE920966A1 (en) 1992-10-07
HU217969B (hu) 2000-05-28
HU9201033D0 (en) 1992-06-29
HUT68242A (en) 1995-06-28
CZ91692A3 (en) 1993-01-13
KR920018036A (ko) 1992-10-21
HK123595A (en) 1995-08-04
IL101395A (en) 1996-10-16
CN1113435A (zh) 1995-12-20
IS3828A (is) 1992-09-28
PH30493A (en) 1997-05-28
EP0506434A1 (en) 1992-09-30
IS1746B (is) 2000-07-11
ATE118770T1 (de) 1995-03-15
CN1066067A (zh) 1992-11-11
EP0506434B1 (en) 1995-02-22
NO304311B1 (no) 1998-11-30
CA2064108A1 (en) 1992-09-28
ES2072095T3 (es) 1995-07-01
IE67383B1 (en) 1996-03-20
FI106260B (fi) 2000-12-29
AU1312292A (en) 1992-10-01
DE69201451T2 (de) 1995-10-12
RU2055073C1 (ru) 1996-02-27
CZ282529B6 (cs) 1997-08-13
US5356918A (en) 1994-10-18
US5298516A (en) 1994-03-29
JPH0780859B2 (ja) 1995-08-30
CN1096265C (zh) 2002-12-18
DK0506434T3 (da) 1995-07-24
FI921340L (fi) 1992-09-28
JPH05213910A (ja) 1993-08-24
CA2064108C (en) 2000-09-26
NZ242154A (en) 1993-09-27
AU647599B2 (en) 1994-03-24
FI921340A0 (fi) 1992-03-26
IL101395A0 (en) 1992-11-15
KR0152097B1 (ko) 1998-10-15
DE69201451D1 (de) 1995-03-30
NO921159D0 (no) 1992-03-25
HU211969A9 (en) 1996-01-29
TW226015B (enExample) 1994-07-01

Similar Documents

Publication Publication Date Title
CN1160343C (zh) 依赖于细胞周期蛋白激酶的氨基噻唑抑制剂
CN100338044C (zh) Hiv蛋白酶抑制剂、含有它们的组合物、其药物应用及其合成原料
CN1190434C (zh) 新的杂环化合物、其制备方法和含有它们的药物组合物及其在治疗糖尿病和相关疾病中的应用
CN1095710A (zh) 酶抑制剂
CN1031824C (zh) 新的噻唑烷酮和噁唑烷酮衍生物的制备方法
CN1711258A (zh) 嘧啶化合物
CN1106017A (zh) 核苷酸膦酸酯衍生物
CN1434811A (zh) 用于治疗炎性、免疫或心血管疾病的新的p2x7受体拮抗剂
HK1046134A1 (en) Novel lipoic acid derivatives, their preparation, and pharmaceutical compositions containing them
CN1768058A (zh) 作为黑皮质素受体激动剂的咪唑并吡啶衍生物
CN1198827C (zh) 精选的K－252a衍生物
CN1993363A (zh) 1,3－二取代的杂芳基nmda/nr2b拮抗剂
CN1029963C (zh) 噻嗪或噁嗪的苯并或萘并衍生物的制备方法
CN1124734A (zh) 噻嗪-或硫氮杂䓬衍生物
CN1516695A (zh) 用作抗病毒剂的芳基磺酰胺类化合物
CN101076525A (zh) 用作肿瘤坏死因子－α抑制剂的稠合三环化合物
CN1035614C (zh) 亚苄基衍生物
CN1103534A (zh) 具有抗精神病作用的化合物
CN1019388B (zh) 新型n-烷磺酰苯胺衍生物的制备方法
CN1071665A (zh) 唑烷酮衍生物
CN1993358A (zh) 作为趋化因子受体拮抗剂的噻唑衍生物
CN1522250A (zh) 带有五元环基团的环状二胺化合物
CN1066725C (zh) 旋光性噻唑烷酮衍生物
CN1852907A (zh) 2－氨基－5－苯甲酰基噻唑npy拮抗剂
CN100341873C (zh) 吡啶并[2,3－d]嘧啶－7－羧酸衍生物,其制造和作为药剂的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C15 Extension of patent right duration from 15 to 20 years for appl. with date before 31.12.1992 and still valid on 11.12.2001 (patent law change 1993)
OR01 Other related matters
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee